| Recommendations of the Canadian Consensus Group onthe Management of Chronic Myeloid Leukemia [12]
|
2006 |
✓ |
50 |
50 |
✓ |
| Updated recommendations from the Canadian Nationalconsensus meeting on HER2/neu testing in breast cancer[13]
|
2007 |
✓ |
7 |
17 |
✓ |
| Colorectal Cancer Association of Canada ConsensusMeeting on Practice Guidelines - Raising the Standard ofCare in Canada for Early Stage Rectal Cancer [14]
|
2009 |
✓ |
22 |
64 |
✓ |
| The role of the Epidermal Growth Factor Receptor TyrosineKinase Inhibitors as Therapy for Advanced, Metastatic andRecurrent Non-Small Cell Lung Cancer: A Canadian NationalConsensus Statement [15]
|
2009 |
✓ |
67 |
46 |
✓ |
| Consensus recommendations for the use of anti-EGFRtherapies in metastatic colorectal cancer [16]
|
2010 |
|
6 |
54 |
|
| Eastern Canadian Colorectal Cancer ConsensusConference: setting the limits of resectable disease [17]
|
2010 |
✓ |
32 |
21 |
✓ |
| Consensus recommendations for the diagnosis andmanagement of well-differentiated gastroenterohepaticneuroendocrine tumours: a revised statement from aCanadian national expert group [18]
|
2010 |
✓ |
23 |
79 |
✓ |
| Diagnosis and management of hepatocellular carcinoma:results of a consensus meeting of The Ottawa Hospital Cancer Centre [19]
|
2010 |
✓ |
33 |
25 |
✓ |
|
Consensus Statements pre IOM 2011 (n = 8), Mean (95% Confidence Interval)
|
30 (16, 44)
|
45 (29, 60)
|
|
| Multidisciplinary Canadian consensus recommendations forthe management and treatment of hepatocellular carcinoma [20]
|
2011 |
✓ |
56 |
75 |
✓ |
| Canadian Expert Group consensus recommendations: KRAStesting in colorectal cancer [21]
|
2011 |
|
19 |
58 |
|
| Report from the 13th Annual Western CanadianGastrointestinal Cancer Consensus Conference [22]
|
2012 |
|
43 |
46 |
|
| Consensus recommendations for cancer rehabilitation:research and education priorities [23]
|
2013 |
|
14 |
79 |
|
| Endocrine therapy for postmenopausal women withhormone receptor–positive her2–negative advancedbreast cancer after progression or recurrence on nonsteroidal aromatase inhibitor therapy: a Canadian consensus statement [24]
|
2013 |
✓ |
40 |
63 |
✓ |
| Eastern Canadian Colorectal Cancer ConsensusConference: standards of care for the treatment of patients with rectal, pancreatic, andgastrointestinal stromaltumours and pancreatic neuroendocrine tumours [25]
|
2013 |
|
29 |
33 |
|
|
Consensus Statements post IOM 2011 (n = 6), Mean (95% Confidence Interval)
|
34 (21, 46)
|
59 (45, 73)
|
|
|
Clinical Practice Guidelines
|
| Bortezomib in Multiple Myeloma and Lymphoma: Asystematic review and clinical practice guideline [26]
|
2006 |
|
82 |
88 |
|
| Guidelines for the diagnosis and management of carcinoidtumours, part 1: the gastrointestinal tract. A statement from a Canadian National Carcinoid Expert Group [27]
|
2006 |
|
20 |
13 |
|
| The role of oxaliplatin combined with 5-fluorouracil andfolinic acid in the first- and second-line treatment of advanced colorectal cancer: a systematic review and clinical practice guideline [28]
|
2006 |
|
74 |
21 |
|
| Canadian Recommendations for the Treatment ofGlioblastoma Multiforme [29]
|
2007 |
✓ |
19 |
17 |
✓ |
| Melanoma Disease Site Group of Cancer Care Ontario’sProgram in Evidence-Based Care Mot. Temozolomide for the Treatment of MetastaticMelanoma: A PracticeGuideline [30]
|
2007 |
|
80 |
92 |
|
| Ifosfamide-based combination chemotherapy in advancedsoft tissue sarcoma: a systematic review and clinical practice guideline [31]
|
2007 |
|
61 |
96 |
|
| Management of Single Brain Metastases: A PracticeGuideline [32]
|
2007 |
|
79 |
92 |
|
| Alemtuzumab in Chronic Lymphocytic Leukemia: ASystematic Review and Clinical Practice Guideline [33]
|
2007 |
|
81 |
100 |
|
| Single-Agent Interleukin-2 in the Treatment of MetastaticMelanoma: A Clinical Practice Guideline [34]
|
2007 |
|
78 |
100 |
|
| Biochemotherapy for the Treatment of MetastaticMalignant Melanoma: A Clinical Practice Guideline [35]
|
2008 |
|
43 |
75 |
|
| Dose-intensive Chemotherapy with Growth Factor or Autologous Bone Marrow/Stem Cell Transplant Support inFirst-line Treatment of Advanced or MetastaticAdult Soft Tissue Sarcoma – A Clinical PracticeGuideline [36]
|
2008 |
|
89 |
100 |
|
| Epidermal growth factor receptor targeted therapy in stageIII and IV head and neck cancer [37]
|
2010 |
|
85 |
79 |
|
| Follow-up for women after treatment for cervical cancer[38]
|
2010 |
|
78 |
79 |
|
|
Clinical Practice Guidelines pre IOM 2011 (n = 13) Mean (95% Confidence Interval)
|
67 (54, 80)
|
73 (55, 91)
|
|
| Canadian College of Medical Geneticists guidelines for theindications, analysis, and reporting of cancer specimens [39]
|
2011 |
|
18 |
46 |
|
| Systemic therapy for advanced gastric cancer: a clinicalpractice guideline [40]
|
2011 |
|
84 |
83 |
|
| Survivorship services for adult cancer populations: a pan-Canadian guideline [41]
|
2011 |
|
84 |
96 |
|
| Invasive mediastinal staging of non-small-cell lung cancer: aclinical practice guideline [42]
|
2011 |
|
75 |
83 |
|
| Management of a suspicious adnexal mass: a clinicalpractice guideline [43]
|
2012 |
|
80 |
63 |
|
| Lenalidomide in multiple myeloma – a practice guideline[44]
|
2013 |
|
75 |
83 |
|
| Chemotherapy (gemcitabine, docetaxel plus gemcitabine,doxorubicin, or trabectedin) in inoperable, locallyadvanced, recurrent, or metastatic uterineleiomyosarcoma: a clinical practice guideline [45]
|
2013 |
|
82 |
88 |
|
| Role of endolaryngeal surgery (with or without laser)compared with radiotherapy in the managementof early (T1) glottic cancer: a clinical practiceguideline [46]
|
2013 |
|
74 |
79 |
|
| Surgical margins and handling of soft-tissue sarcoma inextremities: a clinical practice guideline [47]
|
2013 |
|
77 |
100 |
|
| Liver resection for colorectal cancer metastases [48]
|
2013 |
|
80 |
83 |
|
| A pan-Canadian practice guideline and algorithm:screening, assessment, and supportive care ofadults with cancer-related fatigue [49]
|
2013 |
|
75 |
38 |
|
|
Clinical Practice Guidelines post IOM 2011 (n = 11) Mean (95% Confidence Interval)
|
73 (62, 84)
|
77 (65, 88)
|
|
